CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

lorlatinib

Last Updated: June 10, 2021
Result type: Reports
Project Number: PC0249-000
Product Line: Reimbursement Review

Generic Name: lorlatinib

Brand Name: Lorbrena

Manufacturer: Pfizer Canada

Therapeutic Area: ALK-positive locally advanced or metastatic non-small cell lung

Indications: Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)

Manufacturer Requested Reimbursement Criteria1: Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)

Submission Type: Initial

Tumour Type: Lung

Project Status: Pending

Call for patient/clinician input open: June 10, 2021

Call for patient/clinician input closed: July 12, 2021

Anticipated Date: June 18, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback